Join your fellow Cancer Center Colleagues at our ASCO 2026 Reception Monday Night 8:30 - 11:00 PM #ASCO26 RSVP Here: ci4cc.org/asco-2026-rsvp

We’re proud to announce we've partnered with Colla Health to expand access to behavioral health services for patients receiving cancer care in community-based settings! Read this week's news release to learn more here: hubs.li/Q04l84fP0 #Partnership #CollaHealth #WeAreAON

Ci4CC Membership Input for Podcast Series Launch We invite you to join an open discussion as we plan the launch of our new podcast series. 📅 Every Friday at 12:00 PM (Noon Pacific Time) June and July: These sessions are designed to gather ideas, topics, and feedback from the community and to help shape the direction of the series. Join the Discussion:  We welcome all members and colleagues interested in contributing to the development of this exciting new program ci4cc-org.zoom.us/j/83687252…

#FollowFriday Rachel Voss, MD, is a surgical oncologist specializing in sarcoma care @MoffittNews. Dr. Voss cares for patients with extremity sarcomas, complex retroperitoneal and abdominal sarcomas, GISTs, and benign and malignant adrenal tumors. Go give her a follow! @RachelKVossMD

🤖 #ArtificialIntelligence 🏥 #PrecisionMedicine 🧬#VelazquezVillarrealLab - @cityofhope at #FOGBoston2026 @FoGenomics Enjoying engaging conversations with @Dr_CJackson  and Nelson Freeburg from @Penn, fellow speakers on the #Cancer #Omics Stage at #FOG #FOG26 @FLGenomics

Week at a Glance 1- Oracle | Ci4CC Initiative Work Group A 2-Fueling the Future National Alliance 3-Cancer Intelligence Podcast with Sorena RSVP Here: ci4cc.org/events

👏👏👏Congratulations to our brilliant Leukemia Chief Fellow Dr .@r_sazevedo on being awarded 🥇 Best Overall Fellow of The Year Award at our Leukemia graduation! Very many Congratulations to each & all of our graduating fellows 👏!!!! @TapKadia @garciamanero 🙌

Fresh off of #ASCO26, I'm compelled to share more about how NCI-funded research fuels progress. Our #YourNCI initiative describes how @theNCI—through critical funding and hands-on science across the cancer continuum—advances research, leading to better outcomes for patients.

And what would you do on Monday with the data presented at #ASCO26, @Jani_Chinmay @SylvesterCancer presents on that today during @umiamimedicine Medicine Grand Rounds : Oncology Updates 2025-2026: Practice-Changing Developments Across Cancer Care

ABBV-706 [#SEZ6 #ADC ] in 2L SCLC showed ORR 82% (14/17), with activity even in platinum-refractory/resistant disease and CBR >94% @SclcSMASHERS Early days, but an agent to continue to watch in relapsed SCLC @ASCO #ASCO26 #LCSM @LaurenByersMD @alissajcooper @drshieldsmd

.@PennMedicine at #ASCO26 ft. Pearl Subramanian (@PennDGIM), @HenryLitt, @Ron_cology, Kimberley Lee, @StephenBagleyMD (@PennCancer), Elizabeth McDonald (@PennRadiology) & Daniel Lee (@PennUrology) @ASCO tinyurl.com/2csdxucj

Congratulations to our fantastic resident Shreya Shambhavi, invited back for the second year in a row to present her research! Strong work! #ASCO26, @RutgersCancer @RWJBarnabas

GBM AGILE leadership gathering at #ASCO26 Trial leadership met to discuss innovative design enhancements and identify opportunities to further improve operational efficiency while maintaining scientific rigor and maximizing learning. 🔎 Since launching in 2019, eight investigational therapies have entered the trial. Sites in six countries on three continents have screened over 2700 patients. 🌏 In other recent highlights: Primary analysis of regorafenib was published in JCO in April. Thank you trial leadership for your dedication to accelerating the discovery, evaluation, and development of new treatment options for patients with #glioblastoma. 🧠 We are #FasterTogether! 🙌 #GBMAGILE

At #ASCO26, we caught up with Hans Lee of @SarahCannonDocs, who shared the initial results from the LINKER-AL2 trial evaluating linvoseltamab in patients with R/R systemic AL #Amyloidosis. Click here to watch: 👉 ow.ly/AOxj50Z70uz #RareDisease #HemOnc #Hematology #ImmunoOnc @ASCO

🆕 #ASCO26 data in unresectable #HCC. Ghassan K. Abou-Alfa, MD, PhD, FASCO, of @MSKCancerCenter discusses efficacy and safety findings from the phase III EMERALD-3 trial evaluating immunotherapy-based combinations with TACE. 🎥 Watch here: ascopost.com/videos/asco-202…

At #ASCO26, the oncology community came together to share research and advance care. Legend Biotech presented new data across our CAR-T cell therapy portfolio, including early findings in solid tumors and continued data in multiple myeloma. #CellTherapy @ASCO

Can precision medicine improve public health? By combining genomics, big data, and population health strategies, precision public health aims to deliver the right intervention to the right population at the right time. #ASCO2026 #ASCO26 #Cancer #Oncology dailynews.ascopubs.org/do/ca…

🚨New phase 3 data presented at #ASCO26 compared postoperative stereotactic radiation with cesium-131 tile-based radiation following resection of brain metastases. Moffitt’s Peter Forsyth, MD (@PeterForsyth27), discusses the work by @DrJeffWeinberg of @UTMDAnderson and how tile-based radiation could help redefine postoperative care by improving local control and integrating surgery and radiation into a single treatment approach. #MoffittASCO26 x.com/MoffittNews/status/206…

While at #ASCO26, Peter Forsyth, MD (@PeterForsyth27), stopped by the booth to share research exploring patient-derived tumor models to identify potential treatment strategies for melanoma leptomeningeal disease. #MoffittASCO26

During #ASCO26, I spoke with Dr. Patrick Hwu (@PatrickHwuMD ), Moffitt Cancer Center President & CEO about research aimed at improving treatment for brain tumors and melanoma that spreads to the brain. #ASCO26 #MoffittASCO26 @MoffittNews

Five Intensive Days at ASCO 2026 Full of Science and Fun - Annalice Gandini @AnnaliceGandini oncodaily.com/voices/annalic…